Sorrento Directors Say Investor Suit Inadequately Pled
The directors of biopharmaceutical firm Sorrento Therapeutics Inc. told a Delaware Chancery Court judge Thursday that an investor class action doesn't make an adequate argument as to why stock awards to...To view the full article, register now.
Already a subscriber? Click here to view full article